[Breast cancer after treatment of Hodgkin's disease].
OBJECTIVE
Development of diagnostic, therapeutic and preventive measures for breast cancer after cure of Hodgkin disease.


METHODS
Presentation of 4 patients treated conjointly by the Radiotherapy and Gynaecology Surgery Departments of the Rennes University Hospital.


RESULTS
Illustrations of difficult management of breast cancer at different stages of diagnosis and therapy.


CONCLUSIONS
A past history of treated Hodgkin disease is a factor of risk for breast cancer and suggests the need for annual mammography screening 10 years after the end of treatment. Though more difficult, mastectomy is recommended over conservative radiosurgical treatment. The choice of drugs for adjuvant chemotherapy should rely on Hodgkin protocols and take into account heart function. Long-term carcinogenic effects of Hodgkin disease treatments requires modulation of the different treatment protocols as a function of stage, clinical and histological factors of prognosis and patient age.
Levêque
J
J
Service de Gynécologie-Obstétrique B, CHRU, Rennes.
Meunier
B
B
Poulain
P
P
Blanchot
J
J
Dugast
J
J
Le Prise
E
E
Grall
J Y
JY
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D000328:Adult; D000359:Aftercare; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008466:Mechlorethamine / Q000009:adverse effects; D009381:Neoplasms, Radiation-Induced / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011859:Radiography; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone
Cancer du sein après traitement de maladie de Hodgkin.